This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Jul 2011

MSDC Receives Funding for Alzheimer's Drug Study

The study will evaluate the safety profile and effects of the drug on brain glucose use in patients aged 55-85 with mild Alzheimer's disease.

Metabolic Solutions Development Company has received a $773,000 grant from the Alzheimer's Drug Discovery Foundation to conduct a Phase IIa trial of MSDC-0160, used for the treatment of metabolic diseases associated with altered mitochondrial function.

 

The Alzheimer's Drug Discovery Foundation granted MSDC $100,000 in 2009 for the pre-clinical study of the drug, which demonstrated positive effects in a mouse model of Alzheimer's disease.

 

The double-blind and, placebo-controlled study will evaluate the safety profile and effects of the drug on brain glucose use in patients aged 55-85 with mild Alzheimer's disease.

 

MSDC president and chief scientific officer Jerry Colca said the study will help determine if MSDC

Related News